Connecticut is currently home to 1213 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
NCT06136195
Recruiting
The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.
Gender:
ALL
Ages:
Between 21 years and 50 years
Trial Updated:
08/12/2024
Locations: Connecticut Mental Health Center (SAC and SATU), New Haven, Connecticut
Conditions: Alcohol Consumption, Heavy Drinker, Alcohol Use Disorder (AUD)
Register for Updates
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
NCT02811510
Recruiting
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2024
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut
Conditions: Cannabis
Register for Updates
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
NCT02781519
Recruiting
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2024
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut
Conditions: Cannabis
Register for Updates
Reversal of Lipid-Induced Insulin Resistance
NCT02193295
Recruiting
The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes. Hepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydroxybutyrate).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/12/2024
Locations: Magnetic Resonance Research Center (MRRC), New Haven, Connecticut
Conditions: Insulin Resistance, NAFLD
Register for Updates
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
NCT02805023
Recruiting
Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal pharmacological treatment or control of risk factors and/or had a revascularization failure, and do not have the option of further revascu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Peripheral Arterial Disease, Peripheral Vascular Disease, Chronic Limb-Threatening Ischemia
Register for Updates
Neurofeedback From the Supplementary Motor Area for Tourette Syndrome
NCT05558566
Recruiting
This is a clinical trial where adolescents aged 10-16 years old with Tourette Syndrome (or chronic tic disorder) are randomized to receive either real-time functional magnetic resonance imaging (fMRI) neurofeedback targeting the supplementary motor area (for the experimental intervention) or real-time fMRI neurofeedback (NF) from a control region (for the control intervention).
Gender:
ALL
Ages:
Between 10 years and 16 years
Trial Updated:
08/09/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Tourette Syndrome in Adolescence
Register for Updates
Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs
NCT06411223
Recruiting
This study addresses real-world use of long-acting injectable cabotegravir/rilpivirine (CAB/RPV LA) by evaluating implementation and clinical outcomes of a pharmacist-led collaborative drug therapy management model (CDTM+) that will be expanded for telehealth outreach to women with health-related social needs (HRSN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Yale Clinical and Community Research, New Haven, Connecticut
Conditions: Hiv
Register for Updates
Single Session Intervention to Promote Hope
NCT06375876
Recruiting
The purpose of this study is to develop a brief, self-guided single-session intervention (SSI) that targets the development of, or increase in, hope, and pilot test it for the primary outcomes of feasibility, acceptability/likeability, safety, and changes in hope, and the secondary outcomes of self-worth, empowerment, and emotional wellbeing among women experiencing intimate partner violence (IPV). The study will be conducted in 2 stages: intervention development (Intervention Development Stage)... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: The Consultation Center at Yale, New Haven, Connecticut
Conditions: Domestic Violence
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Imaging SV2A in Mood Disorders
NCT02734602
Recruiting
This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD.... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/08/2024
Locations: PET Center, New Haven, Connecticut
Conditions: Major Depressive Disorder, Post-Traumatic Stress Disorder
Register for Updates
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates